Dry Eye Syndrome Therapeutics Pipeline to Develop with Maximum Drugs Being Derived from Natural Sources

The study analyzed that the dry eyesyndrome therapeutics pipeline comprises approximately 50 drug candidates in different stages of development.

According to the research findings, most of the drug candidates of dry eye syndrome pipeline are being developed to be administered by topical route.

Download Report Sample at: https://www.psmarketresearch.com/market-analysis/dry-eye-syndrome-therapeutics-pipeline-analysis/report-sample

InSite Vision (A Sun Pharmaceutical Industries Ltd. company) is using DuraSite technology platform for the development of their drug candidates for the treatment of dry eye syndrome. DuraSite is a drug delivery vehicle that stabilizes small molecules in a polymeric mucoadhesive matrix.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=dry-eye-syndrome-therapeutics-pipeline-analysis

The research found that various companies use natural sources for the development of dry eye syndrome therapeutics pipeline that includes, but not limited to, MC2 Therapeutics and RegeneRx Biopharmaceuticals, Inc.

Some of the other key players developing drugs for the treatment of dry eye syndrome include Ocular Therapeutix, Inc., LTT Bio-Pharma, HanAll BioPharma Co., Ltd. and others.

Dry Eye Syndrome Therapeutics Pipeline Analysis

·         By Phase

·         By Route of Administration

·         By Molecule Type

·         By Company

Contact:

Mr. Kundan Kumar

Manager – Client Partner

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +18887787886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook